TCT-226 Complete versus culprit-only revascularization in patients with multi-vessel coronary disease undergoing primary percutaneous coronary intervention: An updated meta-analysis of randomized trials  by Elgendy, Islam Y. et al.
B88 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5ACUTE MYOCARDIAL INFARCTIONTuesday, October, 13, 2015, 4:00 PM-6:00 PM
Abstract nos: 226 - 274
TCT-226
Complete versus culprit-only revascularization in patients with multi-
vessel coronary disease undergoing primary percutaneous coronary
intervention: An updated meta-analysis of randomized trials
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Anthony A. Bavry1
1University of Florida, Gainesville, FL
BACKGROUND Current guidelines recommend against revasculari-
zation for non-culprit signiﬁcant coronary lesions at the time of pri-
mary percutaneous coronary intervention (PCI). The aim of this study
was to evaluate outcomes for patients with multi-vessel coronary
disease who underwent complete versus culprit-only revasculariza-
tion at the time of primary PCI.
METHODS Electronic databases and major conference proceedings were
searched for studies that randomized ST-elevation myocardial infarction
(MI) patients with multi-vessel disease to a complete versus culprit-only
revascularization strategy. The primary outcome was the combined
outcome of all-cause mortality or MI. Random effects summary risk ratios
(RR) were constructed using a DerSimonian–Laird model.
RESULTS A total of 7 studies with 1,939 patients were available for
analysis. The median procedure time and contrast volume was higher
in the complete revascularization group versus the culprit-only group
(67.3  5.3 versus 43.0  1.1 min, p <0.001, and 284.5  10.9 versus
185.7  9.8 ml, p <0.001, respectively). At a mean follow-up of 25
months, complete revascularization was associated with a non-sig-
niﬁcant reduction in the risk of all-cause mortality or MI (RR 0.69, 95%
conﬁdence interval (CI) 0.42-1.12, p¼0.14). Complete revasculariza-
tion was associated with a reduced risk of major adverse cardiac
events (MACE) (RR 0.61, 95% CI 0.45-0.81, p<0.001), due to a signif-
icant reduction in urgent revascularization (RR 0.46, 95% CI 0.29-
0.70, p<0.001). The risk of major bleeding and contrast-induced ne-
phropathy was similar with both approaches (RR 0.83, 95% CI 0.41-
1.71, p¼0.62, and RR 0.94, 95% CI 0.42-2.12, p¼0.82).
CONCLUSIONS Complete revascularization of all signiﬁcant coronary
lesions at the time of primary PCI was associated with a reduction inthe risk of MACE due to reduction in the risk of urgent revasculari-
zation. There was a trend towards reduced risk of all-cause mortality
or MI with complete revascularization. This approach appears to be
safe, with no excess major bleeding or contrast-induced nephropathy.
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BACKGROUND Recent randomized trials have failed to demonstrate
clinical beneﬁt from aspiration thrombectomy prior to primary
percutaneous coronary intervention (PCI) in patients with ST-eleva-
tion myocardial infarction (STEMI). However, it is unclear whether
aspects of this procedure (i.e. co-administration of intravenous
glycoprotein IIb/IIIa inhibitors or ischemic time) might modify any
clinical beneﬁts.
METHODS Electronic databases were searched for trials that ran-
domized STEMI patients to aspiration thrombectomy prior to PCI
versus conventional PCI. Summary estimates were constructed using
a DerSimonian-Laird model. Random effects meta-regression for the
logarithm of the relative risk (RR) for various clinical outcomes versus
the average percentage of glycoprotein IIb/IIIa inhibitor usage and
ischemic time were conducted.
RESULTS A total of 17 trials with 20,960 patients were available for
analysis. The weighted mean follow-up duration was 3.7 months.
Aspiration thrombectomy was not associated with a signiﬁcant
reduction in the risk of mortality (relative risk (RR) 0.89, 95% conﬁ-
dence interval (CI) 0.76-1.04, p¼0.13), re-infarction (RR 0.93, 95%
0.73-1.17, p¼0.52), the combined outcome of mortality or re-infarction
(RR 0.90, 0.79-1.02, p¼0.11), major adverse cardiac events (MACE) (RR
0.90, 95% CI 0.81-1.00, p¼0.06), or stent thrombosis (RR 0.82, 95% CI
0.62-1.08, p¼0.15). Aspiration thrombectomy was associated with a
non-signiﬁcant increase in the risk of stroke (RR 1.45, 95% CI 0.96-
2.21, p¼0.08). The ﬁgure summarizes the summary estimates for the
main outcomes assessed. Meta-regression analysis did not identify a
difference for the log RR of mortality, re-infarction, the combined
outcome of mortality or re-infarction, and MACE with intravenous
glycoprotein IIb/IIIa inhibitors (p¼0.17, 0.70, 0.50, and 0.77, respec-
tively) and with ischemic time (p¼0.29, 0.66, 0.58, and 0.16, respec-
tively). Meta-regression for the outcomes of stent thrombosis and
stroke was not possible due to limited studies available for analysis.
CONCLUSIONS Aspiration thrombectomy prior to primary PCI is not
associated with any beneﬁt on clinical endpoints and might increase
